We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Microfilarial Antigen Diagnoses Lymphatic Filariasis Infections

By LabMedica International staff writers
Posted on 08 Jun 2022
Print article
Image: Immunolocalization of BmR1 homologues showing immunohistochemical results from worm sections that were processed (Photo courtesy of Washington University School of Medicine)
Image: Immunolocalization of BmR1 homologues showing immunohistochemical results from worm sections that were processed (Photo courtesy of Washington University School of Medicine)

Lymphatic filariasis is a neglected tropical disease caused by the filarial nematodes Wuchereria bancrofti, Brugia malayi and Brugia timori. Lymphatic filariasis (LF) is a deforming and disabling disease caused by parasitic nematodes that are transmitted by mosquitoes.

Antibodies to some filarial antigens become detectable in blood sooner after exposure or infection, than microfilaria (Mf) or circulating filarial antigen (CFA). Furthermore, antibody assays may be more sensitive than tests for CFA or Mf for detecting filarial infections or exposure to infection in children.

Infectious Disease Specialists at the Washington University School of Medicine (St Louis, MO, USA) report the discovery and characterization of a novel W. bancrofti antigen, Wb-Bhp-1, which is a homologue of the Brugia malayi protein used in antibody tests to monitor filariasis elimination in areas of Asia where LF is caused by Brugia species. The team used various techniques to study the antigen diagnostic potential, including cloning and expression, tissue fixation and immunohistochemistry, immunoblot analysis, and indirect ELISA. They tested sera or plasma from patients infected with W. bancrofti, B. malayi, Onchocerca volvulus and Loa loa. Slides were examined on an Olympus -BX40 microscope and photographed on an Olympus DP70 microscope digital camera (Olympus, Tokyo Japan).

The scientists reported that immunohistology showed that anti-Wb-Bhp-1 antibodies primarily bind to Mf. Plasma from 124 of 224 (55%) microfilaremic individuals had IgG4 antibodies to Wb-Bhp-1 by ELISA. Serologic reactivity to Wb-Bhp-1 varied widely with samples from different regions (sensitivity range 32%–92%), with 77% sensitivity for 116 samples collected from microfilaremic individuals outside of sub-Saharan Africa. The team screened sera from people infected with W. bancrofti, and 12 of 13 (92%) reacted with Wb-Bhp-1 by immunoblot. The scientists tested 224 sera from individuals with W. bancrofti microfilaremia collected in Sri Lanka, India, Papua New Guinea, Egypt and Côte d’Ivoire. They found that 124/ 224 (55%) sera had anti-Wb-Bhp-1 IgG4 ELISA titers above the threshold of 0.2 OD490, using a BioTek ELx808 plate reader (Agilent Technologies, Santa Clara, CA, USA).

The authors concluded that Wb-Bhp-1, a W. bancrofti homologue of BmR1, is a promising microfilarial antigen for diagnosis of bancroftian filariasis. Specificity testing showed that the Wb-Bhp-1 ELISA had low-level cross-reactivity with samples from people with onchocerciasis or loiasis. Wb-Bhp-1 serology may be especially useful in countries where the combination of ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) can be used to accelerate LF elimination. The study was published on May 23, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Washington University School of Medicine 
Olympus 
Agilent Technologies

New
Gold Supplier
Creatinine/eGFR Meter
Nova Max Pro
New
HPLC System
Jasper HPLC System
New
Cytomegalovirus ELISA Test
Captia Cytomegalovirus (CMV) IgM EIA
New
Automated Hematology Workstation
XN-3000

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.